Clinical Trial Update: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

Biogen's Phase 3 efficacy and safety study of BG00012 (dimethyl fumarate) in pediatric Relapsing-Remitting Multiple Sclerosis has completed. No results are deta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED